cosmetics-biomarkers-2019-keynote

7 / 7

Page 18
Notes:
allied
academies
Case Reports in Surgery and Invasive Procedures | Volume 3
Biomarkers
Plastic and Cosmetic Surgery
International Conference on
International Conference on
Joint Event
&
March 11-12, 2019 | London, UK
Although a significant improvement was made in slowing
cancer growth and progression during last several
decades, the failure to eradicate cancer stem cells has become
amajor roadblock for curing some cancers. In general, tobetter
understand how cancer stem cells survive and proliferate, it
is critical to develop biomarkers for monitoring cancer stem
cells during disease initiation, progression and treatment.
In this study, we aim to develop leukotriene B4 (LTB4) as a
novel biomarker for monitoring the presence and function of
leukemia stem cells (LSCs) in chromic myeloid leukemia (CML)
induced by the BCR-ABL oncogene. BCR-ABL tyrosine kinase
inhibitors are effective in treating chronic phase CML but are
unlikely to cure the disease as they do not eradicate LSCs. For
developing curative therapeutic regimens for CML, abiomarker
is needed for monitoring LSCs to evaluate the efficacy of new
therapies. We have previously found that the arachidonate
5-lipoxygenase (5-LO) gene (Alox5) is a key survival-regulatory
gene in LSCs (Chen et al. Nature Genetics 41:783-792, 2009).
Because a known function of 5-LO (encoded by Alox5) is to
produce leukotrienes with leukotriene B4 (LTB4) as a major
form, LTB4 may serve as a novel biomarker for monitoring
LSCs in CML. Importantly, Alox5 is not required by normal
hematopoietic stem cells, suggesting that LTB4 could be a
specific biomarker for LSCs. It is worth pointing out that a
method for monitoring LSCs in CML has not been developed,
and LTB4 would be the first biomarker for monitoring LSCs.
Here we intend to determine: 1) LTB4 is an indicator for
the presence and function of LSCs; 2) LTB4 can be used for
monitoring CML remission, relapse and response to an anti-
LSC therapy and 3) LTB4 serves as a biomarker for indicating
the presence and function of human CML stem cells.
Speaker Biography
Shaoguang Li obtained his PhD degree from Tulane University, USA. He did his postdoctoral
iscurrentlyaprofessoratUniversityofMassachusetts
Medical School, USA. He has published some seminal work related to leukemia stem cells
in highly competitive journals such as Nature Genetics, JCI, PNAS, Blood, Leukemia, etc.
e:
Shaoguang Li
University of Massachusetts Medical School, USA
LTB4 as a biomarker for monitoring leukemia stem cells